Abstracts

HIV-1 Resistance Mutations to Integrase Inhibitors Impair Both Integration and Reverse Transcription

Background: Reverse transcription and integration are key steps of the Human Immunodeficiency Virus type 1 (HIV-1) replication, performed respectively by the viral enzyme’s reverse transcriptase (RT) and integrase (IN). Interactions between these two enzymes are critical: IN improves both reverse transcription early steps and processivity, while the RT enhances the integrase strand transfer activity. The…

First-in-Human Phase I Trial of an Adjuvanted SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine

Background: Next-generation coronavirus (CoV) vaccines must confer broader protection against a range of SARS-CoV-2 variants as well as novel species that may cross over from zoonotic reservoirs in the future. The SARS-CoV-2 recombinant spike ferritin nanoparticle (SpFN) vaccine co-formulated with Army Liposomal Formulation (ALFQ) adjuvant containing monophosphoryl lipid A and QS-21 (SpFN/ALFQ) was previously shown…

PREVENT: Phase I Clinical Trial of a Q-Griffithsin (Q-GRFT) Nasal Spray for Prevention of SARS-CoV-2

Background: The COVID pandemic highlighted the need to develop vaccine alternatives to prevent the spread of SARS-CoV-2, especially in immunosuppressed people. Q-GRFT, a broad-spectrum viral entry inhibitor, functions by binding oligomannose glycans on viral envelopes and is highly potent, with an IC90 of 645 ng/mL against the SARS-CoV-2 BA.5 variant. A nasal spray formulation was…

Remdesivir+Dexamethasone vs Dexamethasone for the Treatment of COVID-19: Real-World Study in the US

Background: Dual therapy with remdesivir (RDV) and dexamethasone (DEX) among patients with COVID-19 has demonstrated improved clinical outcomes compared to DEX monotherapy. We evaluated the effectiveness of RDV+DEX vs. DEX monotherapy by applying and comparing two established methods used to balance two inherently different groups due to confounding by indication in observational research. Methods: Adults…

Remdesivir Reduces Mortality in Immunocompromised Patients Hospitalised for COVID-19 During Omicron

Background: Previous research has established the effectiveness of remdesivir (RDV) in reducing mortality among immunocompromised patients hospitalized for COVID-19. In this study, we present data from the Omicron predominant era (Dec’21-Apr’23) by examining in-hospital all-cause mortality for early RDV initiation vs. not initiating RDV among immunocompromised hospitalized COVID-19 patients. Methods: Using the PINC AI Healthcare…

Disparities in Treatment Initiation by Race and Ethnicity Among Patients Hospitalized for COVID-19

Background: The pandemic has shed light on the heightened risks of morbidity and mortality faced by minority patients hospitalized with COVID-19. However, there is a significant lack of real-world data that explores whether Black inpatients are less likely to receive appropriate pharmaceutical treatment for COVID-19 in the hospital than other racial groups. To address this…

Cabotegravir Stearate (XVIR-110), an InSTI Prodrug, Provides Ultra-Long Acting Cabotegravir Exposure

Background: Cabotegravir stearate (M2CAB) is a novel prodrug of the INSTI cabotegravir (CAB) that forms local and macrophage-distributed M2CAB depots, resulting in ‘flip-flop’ plasma pharmacokinetics (PK) yielding a protracted apparent elimination half-life. M2CAB is formulated as an extended-release injectable suspension (XVIR-110) for intramuscular (IM) administration that may achieve ultra-long-acting therapeutic CAB exposures with infrequent administration.…